🕵️ SAB Biotherapeutics, Inc. ($SABS)
SEC insider & ownership activity, last 12 months · CIK 1833214 · every row links its SEC filing
Insiders were quiet over the last 12 months – no open-market buys or sells. No red-flag 8-Ks in the window.
Insider flow
0 buyers, $0 (0 lots) · 0 sellers, $0 (0 lots)
No open-market insider transactions in the last 12 months.
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Caligan Partners LP | 10.4% | 13G | May 15, 2026 | filing ↗ | |
| Johnson David Edward | 10.4% | 13G | May 15, 2026 | filing ↗ | |
| VIVO Opportunity Fund Holdings, L.P. | 10.0% | 13G | Oct 3, 2025 | filing ↗ | |
| VIVO Opportunity, LLC | 10.0% | 13G | Oct 3, 2025 | filing ↗ | |
| VIVO Opportunity Cayman Fund, L.P. | 10.0% | 13G | Oct 3, 2025 | filing ↗ | |
| VIVO Opportunity Cayman, LLC | 10.0% | 13G | Oct 3, 2025 | filing ↗ | |
| Balyasny Asset Management L.P. | 10.0% | 13G | May 15, 2026 | filing ↗ | |
| BAM GP LLC | 10.0% | 13G | May 15, 2026 | filing ↗ | |
| Balyasny Asset Management Holdings LP | 10.0% | 13G | May 15, 2026 | filing ↗ | |
| Dames GP LLC | 10.0% | 13G | May 15, 2026 | filing ↗ | |
| Dmitry Balyasny | 10.0% | 13G | May 15, 2026 | filing ↗ | |
| Roderick WONG, M.D. | 10.0% | 13G | Feb 14, 2025 | filing ↗ | |
| Commodore Capital LP | 9.9% | 13G | Oct 3, 2025 | filing ↗ | |
| Commodore Capital Master LP | 9.9% | 13G | Oct 3, 2025 | filing ↗ | |
| Robert Egen Atkinson | 9.9% | 13G | Oct 3, 2025 | filing ↗ | |
| Michael Kramarz | 9.9% | 13G | Oct 3, 2025 | filing ↗ | |
| RA Capital Management, L.P. | 9.9% | 13D | Mar 19, 2026 | filing ↗ | |
| Peter Kolchinsky | 9.9% | 13D | Mar 19, 2026 | filing ↗ | |
| Rajeev Shah | 9.9% | 13D | Mar 19, 2026 | filing ↗ | |
| RA Capital Healthcare Fund, L.P. | 9.9% | 13D | Mar 19, 2026 | filing ↗ | |
| Woodline Partners LP | 9.9% | 13G | Nov 14, 2025 | filing ↗ | |
| BVF Partners L P/IL | 9.1% | 13G | Feb 17, 2026 | filing ↗ | |
| BVF INC/IL | 9.1% | 13G | Feb 17, 2026 | filing ↗ | |
| Mark N. Lampert | 9.1% | 13G | Feb 17, 2026 | filing ↗ | |
| BVF GP Holdings LLC | 8.6% | 13G | Feb 17, 2026 | filing ↗ | |
| Perceptive Advisors LLC | 8.4% | 13G | May 15, 2026 | filing ↗ | |
| Joseph Edelman | 8.4% | 13G | May 15, 2026 | filing ↗ | |
| Perceptive Life Sciences Master Fund, Ltd. | 8.4% | 13G | May 15, 2026 | filing ↗ | |
| Millennium Management LLC | 5.1% | 13G | May 1, 2026 | filing ↗ | |
| Millennium Group Management LLC | 5.1% | 13G | May 1, 2026 | filing ↗ | |
| Israel A. Englander | 5.1% | 13G | May 1, 2026 | filing ↗ | |
| Biotechnology Value Fund L P | 5.1% | 13G | Feb 17, 2026 | filing ↗ | |
| BVF I GP LLC | 5.1% | 13G | Feb 17, 2026 | filing ↗ |
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Reg FD disclosure (7.01) | Jul 7, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 7, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 18, 2026 | filing ↗ |
| Material agreement (1.01) | Apr 28, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 28, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Apr 22, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 22, 2026 | filing ↗ |
| Material agreement (1.01) | Mar 17, 2026 | filing ↗ |
| Other events (8.01) | Mar 17, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 17, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Mar 10, 2026 | filing ↗ |
| Other events (8.01) | Mar 10, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 10, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 12, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jan 5, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 5, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 5, 2026 | filing ↗ |
| Other events (8.01) | Dec 29, 2025 | filing ↗ |
| Officer/director changes (5.02) | Sep 30, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Sep 30, 2025 | filing ↗ |
| Officer/director changes (5.02) | Sep 26, 2025 | filing ↗ |
| Shareholder vote (5.07) | Sep 26, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Sep 26, 2025 | filing ↗ |